Literature DB >> 25274201

[Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].

A Gliese1, C-J Busch, R Knecht.   

Abstract

The two available options for primary radiochemotherapy (RCT) of locally advanced head and neck squamous cell carcinoma are discussed in the current study: concomitant and sequential RCT. At the annual meeting of the American Society of Clinical Oncology (ASCO) 2014, results of current trials on the primary nonsurgical therapy of locally advanced head and neck tumors were presented. A selection of the most important trials will be summarized in this article. Studies including cisplatin-based RCT as standard therapy for locally advanced head and neck tumors, alternatives for cisplatin, combination with targeted therapy, application of the epidermal growth factor receptor (EGFR) antibody cetuximab and the comparison of concomitant and sequential RCT are discussed. The first completely recruited phase III trial comparing concomitant and sequential RCT will also be presented.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274201     DOI: 10.1007/s00106-014-2926-1

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  11 in total

1.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

2.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

3.  A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Authors:  R Hitt; J J Grau; A López-Pousa; A Berrocal; C García-Girón; A Irigoyen; J Sastre; J Martínez-Trufero; J A Brandariz Castelo; E Verger; J J Cruz-Hernández
Journal:  Ann Oncol       Date:  2013-11-19       Impact factor: 32.976

4.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

5.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

6.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

7.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

8.  Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

Authors:  Siraj M Ali; R Katherine Alpaugh; Sean R Downing; Philip J Stephens; Jian Q Yu; Hong Wu; Jamie K Buell; Vincent A Miller; Doron Lipson; Gary A Palmer; Jeffrey S Ross; Massimo Cristofanilli
Journal:  J Clin Oncol       Date:  2014-02-10       Impact factor: 44.544

9.  Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Authors:  Arlene A Forastiere; Qiang Zhang; Randal S Weber; Moshe H Maor; Helmuth Goepfert; Thomas F Pajak; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Wade Thorstad; Henry Wagner; John F Ensley; Jay S Cooper
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

10.  Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.

Authors:  A Paccagnella; M G Ghi; L Loreggian; A Buffoli; H Koussis; C A Mione; A Bonetti; F Campostrini; G Gardani; A Ardizzoia; D Dondi; M Guaraldi; R Cavallo; L Tomio; A Gava
Journal:  Ann Oncol       Date:  2009-12-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.